Kalbe Farma, Pharmaceutical Company Owned By Conglomerate Boenjamin Setiawan, Raises Sales Of IDR 19.09 Trillion In The Third Quarter Of 2021

JAKARTA - The pharmaceutical company PT Kalbe Farma Tbk recorded a bright performance in the January-September 2021 period. The sales and net profit of the issuer codenamed KLBF grew significantly in the third quarter of 2021.

In Kalbe Farma's financial report published on the Indonesia Stock Exchange (IDX) website, quoted Monday, October 25, the company owned by conglomerate Boenjamin Setiawan pocketed net sales of Rp. 19.09 trillion in the third quarter of 2021, or grew 11.70 percent from the same period. the previous year Rp17.09 trillion.

In detail, sales of prescription drugs contributed Rp4.19 trillion. Followed by sales of health products of Rp. 2.92 trillion, income from sales of nutrition of Rp. 5.17 trillion, and income from distribution and logistics of Rp. 6.81 trillion.

In line with that, Kalbe Farma's cost of goods sold also increased by 15.98 percent to Rp10.81 trillion in the third quarter of 2021, compared to selling expenses in the same period last year of Rp9.32 trillion.

Thus, KLBF posted a gross profit of IDR 8.28 trillion or grew 6.56 percent from the same period the previous year of IDR 7.77 trillion. At the same time, the selling expense item was recorded at Rp. 4.16 trillion, an increase of 4.26 percent yoy from the figure of Rp. 3.99 trillion.

Meanwhile, general and administrative expenses rose slightly to IDR 1.05 trillion from the January-September 2020 period of IDR 1 trillion. Furthermore, Kalbe Farma experienced a 42.58 percent decrease in other operating income from Rp105.33 billion to Rp60.48 billion.

After deducting other expenses and tax expenses, Kalbe Farma earned a profit for the period attributable to owners of the parent entity of Rp.2.29 trillion at the end of September 2021. This realization grew 12.81 percent from the same period last year which amounted to Rp.2.03 trillion. .